March 25, 2020 in Kineta Press Release

Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Kineta to Present at the Upcoming 2020 Solebury Trout  Virtual Investor Conference

Seattle, WA — (March 24, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Shawn Iadonato, Kineta Chief Executive Officer, will present an overview of the company at the upcoming Solebury Trout Virtual Investor Conference. The 25 minute presentation includes an interactive Q&A with participants prompted to submit questions electronically. Details for the virtual presentation are as follows:

Date: Thursday, March 26th, 2020

Time: 2:30 PM Eastern Time / 11:30 AM Pacific Time

CLICK HERE to access the live presentation on March 26th at 2:30 EDT


Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology and innate immunity to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of private, government and industry partners to advance our innovative products. For more information on Kineta visit our website,, follow us on Twitter at @kinetabio, LinkedIn and Like us on


NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s and its affiliates’ plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s and its subsidiaries’ businesses which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and neither Kineta nor its affiliates undertake any obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy
(206) 378-0400